Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Federal funding cuts imperil next generation of autism researchers
As the International Society for Autism Research’s annual meeting begins, its next president reflects on a brewing crisis.
Federal funding cuts imperil next generation of autism researchers
As the International Society for Autism Research’s annual meeting begins, its next president reflects on a brewing crisis.
Null and Noteworthy: Reanalysis contradicts report of immune memory in astrocytes
The analysis, which has not yet been peer reviewed, attributes the finding to misidentified immune cells instead.
Null and Noteworthy: Reanalysis contradicts report of immune memory in astrocytes
The analysis, which has not yet been peer reviewed, attributes the finding to misidentified immune cells instead.
Documenting decades of autism prevalence; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 28 April.
Documenting decades of autism prevalence; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 28 April.